Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jazz Pharmaceuticals plc JAZZ

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn... see more

Recent & Breaking News (NDAQ:JAZZ)

Free Research Report on Jazz Pharmaceuticals, Inc., Furiex Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc., Prestige Brands Holdings, Inc. and Synta Pharmaceuticals, Inc.

PR Newswire January 30, 2013

The Real Story Behind LEE, CMVT, JAZZ and RENN

Marketwired January 23, 2013

Where Opportunity is Found - Research Report on Jazz Pharmaceuticals plc and Spectrum Pharmaceuticals, Inc.

PR Newswire January 23, 2013

Key to Success, How to Profit: CLSN, GALE, KERX and JAZZ

Marketwired January 11, 2013

Perfect Trade Setups, How to Play CLSN, GALE, KERX and JAZZ

Marketwired January 9, 2013

Jazz Pharmaceuticals to Webcast Presentation at J.P. Morgan Healthcare Conference

PR Newswire January 2, 2013